Myotonic dystrophy
ORPHA:206647Clinical group
Эпидемиология12
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | >1 / 1000 | 189 | Specific population | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.7 | Worldwide | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.78 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.1 | Italy | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.5 | Japan | Value and class |
| Point prevalence | 1-9 / 100 000 | 8.4 | Ireland | Value and class |
| Point prevalence | 1-5 / 10 000 | 13.3 | Croatia | Value and class |
| Point prevalence | 1-5 / 10 000 | 11.6 | New Zealand | Value and class |
| Point prevalence | 1-5 / 10 000 | 20 | Finland | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.22 | Norway | Value and class |
| Point prevalence | 1-5 / 10 000 | 10.9 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | 2 | United States | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)